|306.72||+0.5900||+0.19%||Vol 40.15K||1Y Perf 24.64%|
|May 29th, 2020 09:53 DELAYED|
|- -%||- -%|
|Target Price||290.00||Analyst Rating||Strong Buy 1.40|
|Potential %||-6.42||Finscreener Ranking||★ 40.59|
|Insiders Trans % 3/6/12 mo.||-100/-100/-99||Value Ranking||+ 38.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 55.51|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||26.05B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||96.34||Earnings Date||30th Apr 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.23|
|EPS Growth Next 5 Years %||10.30|
|Avg. Weekly Volume||432.66K|
|Avg. Monthly Volume||508.89K|
|Avg. Quarterly Volume||719.38K|
IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 306.13 per share at the end of the most recent trading day (a 1.73% change compared to the prior day closing price) with a volume of 647.59K shares and market capitalization of 26.05B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 8377 people. IDEXX Laboratories Inc. CEO is Jay Mazelsky.
The one-year performance of IDEXX Laboratories Inc. stock is 24.64%, while year-to-date (YTD) performance is 17.23%. IDXX stock has a five-year performance of 351.52%. Its 52-week range is between 168.65 and 311.97, which gives IDXX stock a 52-week price range ratio of 96.34%
IDEXX Laboratories Inc. currently has a PE ratio of 58.90, a price-to-book (PB) ratio of 232.47, a price-to-sale (PS) ratio of 10.19, a price to cashflow ratio of 56.90, a PEG ratio of 2.32, a ROA of 24.49%, a ROC of 36.13% and a ROE of 548.70%. The company’s profit margin is 17.78%, its EBITDA margin is 26.60%, and its revenue ttm is $2.46 Billion , which makes it $28.93 revenue per share.
Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.23 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Strong Buy (1.4), with a target price of $290, which is -6.42% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IDEXX Laboratories Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.61, ATR14 : 10.08, CCI20 : 166.22, Chaikin Money Flow : 0.03, MACD : 9.17, Money Flow Index : 68.12, ROC : 5.87, RSI : 65.42, STOCH (14,3) : 81.42, STOCH RSI : 1.00, UO : 54.24, Williams %R : -18.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $0), Daniel M. Junius (Option Excercise at a value of $255 800), Daniel M. Junius (Sell at a value of $1 182 432), Giovani Twigge (Option Excercise at a value of $776 084), Giovani Twigge (Sold 19 650 shares of value $4 976 582 ), James F. Polewaczyk (Option Excercise at a value of $1 312 162), James F. Polewaczyk (Sold 16 264 shares of value $4 860 515 ), Jay Mazelsky (Option Excercise at a value of $2 723 032), Jay Mazelsky (Sold 28 000 shares of value $7 390 778 ), Jonathan J. Mazelsky (Option Excercise at a value of $3 457 022), Jonathan J. Mazelsky (Sold 36 000 shares of value $9 613 470 ), Jonathan W. Ayers (Option Excercise at a value of $16 805 588), Jonathan W. Ayers (Sold 891 876 shares of value $246 504 882 ), Kathy V. Turner (Option Excercise at a value of $499 787), Kathy V. Turner (Sold 2 690 shares of value $809 690 ), Lawrence D. Kingsley (Buy at a value of $99 904), M. Anne Szostak (Option Excercise at a value of $383 947), M. Anne Szostak (Sold 12 073 shares of value $3 433 632 ), Michael J. Lane (Option Excercise at a value of $3 182 283), Michael J. Lane (Sold 35 922 shares of value $9 486 897 ), Nimrata Hunt (Option Excercise at a value of $0), Rebecca M. Henderson (Option Excercise at a value of $861 095), Rebecca M. Henderson (Sold 17 396 shares of value $4 924 737 ), Sharon E. Underberg (Option Excercise at a value of $0), Sophie V. Vandebroek (Option Excercise at a value of $1 171 080), Sophie V. Vandebroek (Sold 16 612 shares of value $4 557 538 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.